See also: Clinical Trial
NCT00509145 is a completed randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis. Other study names are MS-LAQ-301, EUDRACT 2007-003226-19.
Side effects as an overall problem
Currently using MS Phase 3 Study Laquinimod
|This item is relevant to you: 5 - 10 years||1||